$15.40
3.49% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US00773J1034
Symbol
SYRE
Sector
Industry

Aeglea BioTherapeutics Inc Stock price

$15.40
+1.83 13.49% 1M
-12.10 44.00% 6M
-7.88 33.85% YTD
-21.47 58.23% 1Y
-22.10 58.93% 3Y
-197.85 92.78% 5Y
-228.85 93.70% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.52 3.49%
ISIN
US00773J1034
Symbol
SYRE
Sector
Industry

Key metrics

Market capitalization $929.45m
Enterprise Value $520.45m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 2.84
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-214.36m
Cash position $564.82m
EPS (TTM) EPS $-3.03
P/E forward negative
Short interest 26.75%
Show more

Is Aeglea BioTherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Aeglea BioTherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Aeglea BioTherapeutics Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Aeglea BioTherapeutics Inc forecast:

Buy
91%
Hold
9%

Financial data from Aeglea BioTherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
4% 4%
-
- Research and Development Expense 169 169
53% 53%
-
-214 -214
36% 36%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -214 -214
36% 36%
-
Net Profit -160 -160
56% 56%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aeglea BioTherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aeglea BioTherapeutics Inc Stock News

Neutral
PRNewsWire
12 days ago
On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts in 2026 & 2027 Reported extended follow-up Phase 1 data for SPY001, supporting that the molecule is well tolerated, has a pharmacokinetic ("PK") profile enabling quarterly or biannual dosing, and provides complete target engagement...
Neutral
PRNewsWire
16 days ago
SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD) SPY001 pharmacokinetic (PK) data up to eight months continues to support a potential best-in-class profile, including a half-life more than three times that of vedolizumab SPY001 pharmacodynamic (PD) data up to eight months showed that a single dose of SPY001 resulted in rapi...
Neutral
PRNewsWire
18 days ago
WALTHAM, Mass. , May 2, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independen...
More Aeglea BioTherapeutics Inc News

Company Profile

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Head office United States
CEO Cameron Turtle
Employees 65
Founded 2013
Website www.spyre.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today